4-[3-(4-methoxyphenoxy)phenyl]-2-sulfanylidene-3,4-dihydro-1H-indeno[1,2-d]pyrimidin-5-one | 1198174-37-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[3-(4-methoxyphenoxy)phenyl]-2-sulfanylidene-3,4-dihydro-1H-indeno[1,2-d]pyrimidin-5-one
• CAS: 1198174-37-6
• 化学式: C₂₄H₁₈N₂O₃S
• 分子量: 414.485
• InChiKey: TXPGGPGYHNTFCB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  91.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1,3-茚满二酮 、 3-(4-甲氧基苯氧基)苯甲醛 、 硫脲 生成 4-[3-(4-methoxyphenoxy)phenyl]-2-sulfanylidene-3,4-dihydro-1H-indeno[1,2-d]pyrimidin-5-one
  参考文献：
  名称：

  Tricyclic 3,4-dihydropyrimidine-2-thione derivatives as potent TRPA1 antagonists

  摘要：

  The transient receptor potential A1 (TRPA1) channel has been implicated in a number of inflammatory and nociceptive processes, and antagonists of the TRPA1 receptor could offer a potential treatment for conditions such as inflammatory or neuropathic pain, airway disorders, and itch. In a high throughput screen aimed at the identification of TRPA1 antagonists, 4-phenyl-2-thioxo-1,2,3,4-tetrahydroindeno[1,2-d]pyrimidin-5-one (1) was identified as a potent TRPA1 receptor antagonist. A series of analogous tricyclic 3,4-dihydropyrimidine-2-thiones has been prepared via the multi-component Biginelli reaction and subsequent derivatization. This has led to TRPA1 antagonists with potencies around 10 nM for both rat and human derived TRPA1 receptors. The activity was shown to reside exclusively in the 4R-enantiomers. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.12.068

文献信息

• [EN] 3,4-DIHYDROPYRIMIDINE TRPA1 ANTAGONISTS<br/>[FR] ANTAGONISTES DES TRPA1 CONSTITUÉS PAR DES 3,4-DIHYDROPYRIMIDINES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009147079A1

  公开（公告）日：2009-12-10

  The present invention is related to novel 3,4-dihydropyrimidine compounds of formula (I) having TRPA1 receptor antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases linked to the modulation of the TRPA1 receptors in animals, in particular humans.

  本发明涉及具有TRPA1受体拮抗性质的新型3,4-二氢嘧啶化合物（I）的药物组合物，包括这些化合物的化学制备过程以及它们在治疗与动物中TRPA1受体调节相关的疾病，特别是人类中的用途。
• 3,4-DIHYDROPYRIMIDINE TRPA1 ANTAGONISTS
  申请人：Gijsen Henricus Jacobus Maria

  公开号：US20110124666A1

  公开（公告）日：2011-05-26

  The present invention is related to novel 3,4-dihydropyrimidine compounds of formula (I) having TRPA1 receptor antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases linked to the modulation of the TRPA1 receptors in animals, in particular humans.
• [EN] USE OF TRPA1 RECEPTOR ANTAGONISTS FOR TREATING DISEASES ASSOCIATED WITH BACTERIAL INFECTIONS<br/>[ES] USO DE ANTAGONISTAS DEL RECEPTOR TRPA1 PARA EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS A INFECCIONES BACTERIANAS<br/>[FR] UTILISATION D'ANTAGONISTES DU RÉCEPTEUR TRPA1 POUR LE TRAITEMENT DE MALADIES ASSOCIÉES À DES INFECTIONS BACTÉRIENNES
  申请人：UNIV MIGUEL HERNANDEZ DE ELCHE

  公开号：WO2013038046A1

  公开（公告）日：2013-03-21

  La presente invención se dirige al uso de un ligando antagonista del receptor TRPA para la preparación de un medicamentodirigido al tratamiento o prevención de enfermedades o disfunciones producidas por infecciones bacterianas o por exposición a endotoxinas bacterianas.
• Tricyclic 3,4-dihydropyrimidine-2-thione derivatives as potent TRPA1 antagonists
  作者：Harrie J.M. Gijsen、Didier Berthelot、Michel A.J. De Cleyn、Ivo Geuens、Bert Brône、Marc Mercken

  DOI：10.1016/j.bmcl.2011.12.068

  日期：2012.1

  The transient receptor potential A1 (TRPA1) channel has been implicated in a number of inflammatory and nociceptive processes, and antagonists of the TRPA1 receptor could offer a potential treatment for conditions such as inflammatory or neuropathic pain, airway disorders, and itch. In a high throughput screen aimed at the identification of TRPA1 antagonists, 4-phenyl-2-thioxo-1,2,3,4-tetrahydroindeno[1,2-d]pyrimidin-5-one (1) was identified as a potent TRPA1 receptor antagonist. A series of analogous tricyclic 3,4-dihydropyrimidine-2-thiones has been prepared via the multi-component Biginelli reaction and subsequent derivatization. This has led to TRPA1 antagonists with potencies around 10 nM for both rat and human derived TRPA1 receptors. The activity was shown to reside exclusively in the 4R-enantiomers. (C) 2011 Elsevier Ltd. All rights reserved.